Recent Company News

• 05:55 AM ET Jul 23, 2025
  

  (RDHL) Investment Analysis and Advice

• 03:38 PM ET Jul 21, 2025
  

  RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

• 09:03 AM ET Jul 21, 2025
  

  RedHill Biopharma receives positive FDA feedback on pathway to approval of RHB-204 for Crohn's disease ($1.86, 0.00)

• 07:25 AM ET Jul 02, 2025
  

  Learn to Evaluate (RDHL) using the Charts

• 12:00 PM ET Jul 01, 2025
  

  RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

• 09:02 PM ET Jun 21, 2025
  

  Long Term Trading Analysis for (RDHL)

• 07:11 AM ET May 13, 2025
  

  RedHill awarded attachment petition to the Court in South Korea on Kukbo Co. Ltd's ("Kukbo") assets ($2.00, 0.00)

• 07:06 AM ET Apr 28, 2025
  

  RedHill Biopharma secures allowance of Chinese patent application for RHB-107 ($2.41, 0.00)

• 07:03 AM ET Apr 16, 2025
  

  RedHill Biopharma announced the new publication of in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity ($2.14, 0.00)

• 07:51 AM ET Apr 10, 2025
  

  RedHill Biopharma reports FY net income ($8.3M) vs year-ago $23.9M ($2.70, 0.00)